FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Stock analysts at HC Wainwright lifted their FY2026 earnings estimates for Q32 Bio in a research report issued on Tuesday, March 10th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.21) for the year, up from their previous forecast of ($2.53). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. HC Wainwright also issued estimates for Q32 Bio’s FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.86) EPS, FY2029 earnings at $0.16 EPS and FY2030 earnings at $0.41 EPS.

Q32 Bio (NASDAQ:QTTB) last posted its earnings results on Tuesday, March 10th. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $4.71. The firm had revenue of $53.74 million for the quarter.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $13.00.

Q32 Bio Stock Up 15.4%

Shares of QTTB stock opened at $6.91 on Thursday. The business’s fifty day moving average is $4.14 and its 200 day moving average is $3.09. The stock has a market cap of $85.02 million, a price-to-earnings ratio of 3.00 and a beta of 0.14. Q32 Bio has a twelve month low of $1.35 and a twelve month high of $7.10.

Insiders Place Their Bets

In other Q32 Bio news, CEO Jodie Pope Morrison sold 9,896 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the transaction, the chief executive officer directly owned 89,104 shares in the company, valued at approximately $401,859.04. This trade represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 16,706 shares of company stock valued at $75,344 in the last 90 days. 40.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Q32 Bio

Several hedge funds and other institutional investors have recently modified their holdings of the stock. HRT Financial LP raised its holdings in Q32 Bio by 66.5% in the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock worth $81,000 after purchasing an additional 9,862 shares during the period. Marshall Wace LLP purchased a new stake in Q32 Bio in the second quarter worth about $25,000. Geode Capital Management LLC increased its position in Q32 Bio by 19.9% in the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock worth $352,000 after buying an additional 17,617 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Q32 Bio in the fourth quarter worth about $66,000. Finally, XTX Topco Ltd bought a new position in shares of Q32 Bio in the fourth quarter worth about $68,000. 31.32% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: Q32 reported a large Q4 2025 beat: EPS $3.65 vs. consensus (‑$1.06) and revenue $53.7M. The company also completed enrollment expansion in the SIGNAL‑AA Phase 2a trial (36‑week topline expected mid‑2026), completed a $10.5M registered direct offering, sold the ADX‑097 asset to Akebia, and reported ~$$48.3M cash plus expected proceeds/milestones — management says this provides runway into Q4 2027. These items explain upside sentiment and improved funding visibility. Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: HC Wainwright materially raised multi‑year EPS forecasts and reiterated a “Buy” rating with a $13 price target — notably FY2030 EPS raised to $0.41 (from $0.11) and FY2029 to $0.16 (from ‑$0.18). The analyst upgrades signal increasing sell‑side confidence in Q32’s pathway to eventual profitability, supporting investor demand.
• Neutral Sentiment: HC Wainwright also published updated quarterly/near‑term estimates for 2026 (Q1–Q4 showing negative EPS between roughly ‑$0.52 and ‑$0.59) — indicating the analyst still expects near‑term losses even as longer‑term estimates improve. The broader consensus full‑year estimate remains deeply negative (about ‑$12.32), so market expectations are uneven.
• Negative Sentiment: Governance and cost risk: a TipRanks piece reports shareholder backlash and rising costs tied to a 2025 stock‑option repricing, which could hurt investor sentiment, create dilution concerns or prompt governance scrutiny. This is a reputational and potential financial headwind. Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.